Cuprina (Cayman) (CUPR) vs Femasys (FEMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cuprina (Cayman) (CUPR) has outperformed Femasys (FEMY) over the past year, losing 78.8% versus a loss of 82.9%. Femasys is the larger company by market cap ($16.8 million vs $11.8 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUPR | FEMY |
|---|---|---|
| Share price | $1.69 | $2.00 |
| Market cap | $11.84M | $16.75M |
| 1-day change | -11.05% | -2.20% |
| YTD return | -40.63% | -82.25% |
| 1-year return | -78.79% | -82.87% |
| 5-year return | — | -98.54% |
| EPS (TTM) | $-1.40 | $-3.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.80 | $22.20 |
| 52-week low | $1.45 | $1.94 |
| Distance from 52-week high | -88.58% | -90.99% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +616.50% |
| Average volume | 94.31K | 722.09K |
| Shares outstanding | 5.24M | 8.38M |
| Employees | 10 | 51 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cuprina (Cayman)
CUPR stock →Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name.
Health Care · Industrial Specialties · 10 employees
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Health Care · Medical/Dental Instruments · 51 employees
CUPR vs FEMY FAQ
Which is bigger, Cuprina (Cayman) or Femasys?
Femasys (FEMY) is larger, with a market capitalization of $16.75M compared with $11.84M for Cuprina (Cayman) (CUPR).
Which stock has performed better over the past year, CUPR or FEMY?
CUPR returned -78.79% over the past 12 months, compared with -82.87% for FEMY (price return, excluding dividends). Past performance does not predict future results.
Are Cuprina (Cayman) and Femasys in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Cuprina (Cayman) and Medical/Dental Instruments for Femasys.